Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut Syndrome ...Middle East

PARAMUS, N.J., Aug. 2, 2021 /PRNewswire/ -- Epygenix Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to EPX-200 for the...

Hence then, the article about epygenix therapeutics receives u s fda orphan drug designation for epx 200 in lennox gastaut syndrome was published today ( Monday 02/08/2021 - 08:00 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut Syndrome )

Also on site :

• Natural gas line rupture stops traffic on 5 Freeway in Castaic
• 30–35 terrorists on radar: Army steps up counterterror ops in J&K; intense vigil amid 'Chillai Kalan'
• Nine Years After Carrie Fisher Died, Billie Lourd Says Mom “Lives on Through Joy” With Kids, Dad Bryan Lourd